196 results
Page 5 of 10
8-K
EX-99.1
298t4qcwc40fk jf511u
1 Sep 20
Hepion Pharmaceuticals Completes Final Dosing in Phase 1b Multiple Ascending Dose Study of CRV431
1:27pm
8-K
EX-99.1
orqkf9qqrjm6 selmr
27 Aug 20
Other Events
11:19am
8-K
EX-99.1
dcwsfkdu
12 Aug 20
Hepion Pharmaceuticals Announces Publication of Preclinical Study Evaluating CRV431’s Antiviral Properties
8:46am
8-K
EX-99.1
cfpucxxm 5nv7c0jy5dk
5 Aug 20
Hepion Pharmaceuticals Announces First NASH Patient Dosed with CRV431 in Phase 2 ‘AMBITION’ Clinical Trial
9:18am
8-K
EX-99.1
cb9g0o4mswtpi
7 Jul 20
Hepion Pharmaceuticals Announces Preclinical Data Supporting Novel Two-Pronged Approach to Treating COVID-19 with CRV431
8:26am
8-K
EX-99.1
8r68f o1st6hig
29 Jun 20
Hepion Pharmaceuticals Announces Advancement to Final Dose Level in Ongoing Multiple Ascending Dose Clinical Study of CRV431
12:00am
8-K
EX-99.1
juzgevi eoibb8l0n
22 Jun 20
Other Events
4:54pm
8-K
EX-99.1
ftf1f
10 Jun 20
Hepion Pharmaceuticals Welcomes Industry Veteran and Drug Development Expert, Dr. Peter Wijngaard, to its Board of Directors
5:04pm
8-K
EX-99.1
jmwbkd
20 May 20
Hepion Pharmaceuticals Announces Advancement to Fourth Dose Level in Ongoing Multiple Ascending Dose Clinical Study of CRV431
4:35pm
8-K
EX-99.1
0bofc13ij5m9lc1jvs
19 May 20
Other Events
8:12am
8-K
2fnnm
14 May 20
Other Events
4:15pm
8-K
n361igjvoxf
30 Mar 20
Other Events
4:05pm
424B5
4ajxre
26 Mar 20
Prospectus supplement for primary offering
9:33pm
8-K
EX-99.1
cjf9vgznlqz gxy2fk
12 Mar 20
Other Events
8:47am
8-K
EX-99.1
7su539t
20 Feb 20
Other Events
9:12am
8-K
EX-1.1
cvokksrh fodzf0c
12 Feb 20
Entry into a Material Definitive Agreement
4:55pm
8-K
EX-99.1
feqoj47
12 Feb 20
Hepion Pharmaceuticals Announces Advancement to Third Dose Level in Ongoing Multiple
4:24pm